Review

Tricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses

Inseok Choi, Hyewon Son and Jea-Hyun Baek

1 School of Life Science, Handong Global University, Pohang, Gyeongbuk 37554, Republic of Korea
* Correspondence: jbaek@handong.edu; Tel.: +82 54 260 1347

Abstract: Tricarboxylic acid cycle (TCA) is a series of chemical reactions in aerobic organisms used to generate energy via the oxidation of acetyl-CoA derived from carbohydrates, fatty acids, and proteins. In the eukaryotic system, the TCA cycle occurs exclusively in the matrix of the mitochondria, which are surrounded by two lipid bilayers and impermeable for polar solutes. The mitochondrial compartmentalization separates energy-producing reactions from energy-consuming ones and retains TCA cycle intermediates, which are small, highly polar, and electrophilic organic carboxylic acids, in mitochondria. NADH and FADH2 produced in the TCA cycle are oxidized in the electron transport chain (ETC) embedded in the inner mitochondrial membrane to generate additional ATP via a process called oxidative phosphorylation. Thereby, the mitochondrion is the organelle staging the most efficient metabolic pathways, including the TCA cycle and oxidative phosphorylation supplying the entire cell with energy in form of ATP [1]. Of note, mitochondria have many functions in addition to metabolism and oxidative phosphorylation. It is critical in detoxification, iron-sulfur cluster biogenesis, intracellular calcium homeostasis, and cell death mechanisms and is the central regulator of intracellular innate immune responses to pathogens [2-7]. Indeed, mitochondria provide stress mediators initiating cell death and autophagy, present adaptor molecules required for the transduction of cellular innate immune signals [2,3], and release mitochondrial components (e.g., mitochondrial DNA, mitochondrial RNA, cytochrome c, reactive oxygen species [ROS]) into the cytosol as danger signals [4] (Figure 1). Mitochondrial DNA and RNA may activate intracellular sensors sensing pathogenic DNA and RNA (e.g., the retinoic-acid-inducible gene [RIG]-I-like proteins, protein kinase R [PKR], the stimulator of interferon genes [STING], mitochondrial antiviral signaling protein [MAVS], cyclic GMP-AMP synthase [cGAS] and interferon-γ-inducible protein 16 [IFI16]) to detect intracellular pathogens [2,3,8-13]. Researchers have demonstrated that mitochondrial DNA leaking from dysfunctioning or disrupted
mitochondria directly activates STING providing a direct potential link between mitochondrial disease and inflammatory response [3,14,15]. A more recent study showed that, under pathologic conditions, mitochondrial RNA is released from dysfunctional mitochondria, in turn, triggering immune activation [13]. Under conditions of cell stress, mitochondria release cytochrome c and ROS inducing apoptosis and cell and tissue destruction [4]. In addition, TCA cycle intermediates may also leak from mitochondria upon cell stress (Figure 1). The intermediates of the TCA cycle take several roles as metabolites in metabolisms, such as insulin secretion and fatty acid synthesis (FAS) inside mitochondria. Furthermore, they are transported in and out of mitochondria through various shuttle mechanisms and are involved in many biological processes. Interestingly, increasing evidence suggests that the TCA cycle intermediates play crucial roles in regulating cellular immunity.

Figure 1. Mitochondrial Danger Signals In Cell Stress

In the last ten years, it has been increasingly recognized that cellular metabolism controls immune cell functions, and it became evident that some metabolic pathways activate, and others suppress immune responses. Innovative systems biology tools have revolutionized metabolic research and are currently providing us with an overwhelming amount of data and new insights, which need to be put together to form a coherent whole. In this review, we present findings from studies focusing on the role of TCA cycle intermediates in cellular immunity and provide a comprehensive systematic overview of the immunologic features of TCA cycle intermediates (Figure 2).

0. Acetyl-CoA

Acetyl coenzyme A (Acetyl-CoA) is a molecule produced in the breakdown of carbohydrates, proteins, and fatty acids. It feeds into the TCA cycle by combining with oxaloacetate to citrate. Although acetyl-CoA is, strictly speaking, not an intermediate of the TCA cycle. Nonetheless, the intramitochondrial levels of acetyl-CoA are essential for sustaining TCA cycle activity. Additionally, acetyl-CoA is a precursor for fatty acids, steroids, and certain amino acids, such as glutamate, proline, and arginine [16]. The most important cellular function of acetyl-CoA is to provide an acetyl group for histone acetylation in the nucleus. Elevated histone acetylation was found to upregulate the expression of glycolytic enzymes, which are related to immune activation [17]. Importantly, acetyl-CoA is generated in multiple compartments, including cytosol. Therefore, it is difficult to estimate to what extent the mitochondrial portion of acetyl-CoA contributes to the expression of glycolytic enzymes. Particularly, the role of mitochondrial acetyl-CoA leaking from mitochondria during cellular stress in cellular immunity has remained elusive [18]. Interestingly, the cytosolic and nucleic levels of acetyl-CoA can increase, when citrate is transported from mitochondria into the cytosol by the dicarboxylate antiporter solute carrier family 25 (SLC25A1; mitochondrial citrate carrier, CIC) and converted into oxaloacetate.
and acetyl-CoA by ATP citrate lyase (ACLY). ACLY-derived cytosolic and nucleic acetyl-CoA, in turn, may drive histone acetylation affecting cellular functions [19-21]. The acetylation of lysine residues on histone H3 is associated with the expression of IL-6 in virus-infected [22] and paraquat (PQ)-treated [23] macrophages, the secretion of MMP-1 and MMP-3 in Mycobacterium tuberculosis-infected macrophages [24] as well as the elevated promoter activity for IL-12p40 [25]. Nevertheless, it remains unclear how histone acetylation regulates specific genes during macrophage activation. Therefore, this research area deserves further investigations in the future [26]. Acetylation can also regulate the function of proteins outside of histone modifications [27]. Specifically, acetylation of the cytoskeletal protein α-tubulin, by the tubulin acetyltransferase MEC17, was shown to regulate IL-10 induction in lipopolysaccharide (LPS)-activated pro-inflammatory macrophages [27]. As such, acetylation can serve as an important signal to govern both pro- and anti-inflammatory cytokine production in macrophages.

Figure 2. TCA Cycle Intermediates

1. Citrate

Citrate is formed in the TCA cycle by the condensation of oxaloacetate and acetyl-CoA, which is catalyzed by citrate synthase. Of note, the cellular levels of citrate are increased in pro-inflammatory macrophages [28-30]. Mitochondrial citrate can inhibit pyruvate dehydrogenase (PDH) and succinate dehydrogenase (SDH) at high concentrations [30]. PDH converts pyruvate to acetyl-CoA and CO2, whereas SDH oxidizes succinate to fumarate in the TCA cycle. Thereby, PDH and SDH catalyze two crucial steps of the TCA cycle, of which the first is the initiation of the TCA cycle and the second the generation of FADH2. Overall, citrate was found to exert inhibitory effects on the TCA cycle promoting ATP-consuming pathways [30-32].

In pro-inflammatory macrophages, mitochondrial citrate exits the mitochondrial matrix and is converted to acetyl-CoA by ACLY after transport to the cytosol by SLC25A1 [33,34]. SLC25A1 is upregulated in pro-inflammatory macrophages in an NF-κB or STAT-dependent manner [29,30,33-35]. Conversely, the inhibition of SLC25A1 leads to the
reduction of inflammatory mediators [34]. In line with this, the export and breakdown of mitochondrial citrate have been linked to the production of several important pro-inflammatory mediators in macrophages, such as NO, ROS, and prostaglandin E2 (PGE2) [29,30,33,35,36]. The decrease in PGE2 production may be due to a decreased availability of citrate as adding exogenous acetate rescues the effect of SLC25A1 inhibition on PGE2 production, suggesting that the cytosolic citrate is an important signal molecule in inflammation [30]. Studies have demonstrated that the upregulation of the ACLY gene precedes SLC25A1 activation in both resting and pro-inflammatory macrophages, although SLC25A1 might be essential for providing the substrate for ACLY activity [33,35]. It is also interesting to note that SLC25A1 mutations that inactivate the citrate export are associated with severe mitochondrial dysfunction [29,37].

2. cis-Aconitate

cis-Aconitate is a TCA cycle intermediate, which is formed during the reversible transformation of citrate to isocitrate by the action of the enzyme aconitase (also known as aconitate hydratase). In this process, cis-aconitate normally does not dissociate from the active site of aconitase. Thus, not much is known about the cellular functions of cis-aconitate. In recent years, cis-aconitate has attracted a lot of attention because it was identified as the precursor of itaconate, which is formed from cis-aconitate through the decarboxylation catalyzed by the immune-responsive gene 1 (IRG1). Itaconate is upregulated upon immune activation, e.g., in response to LPS activation in macrophages, and has strong immunosuppressive properties. As the native itaconate is cell-impermeable, researchers often used structurally modified itaconate derivatives with increased intracellular penetration (e.g., DMI and 4-octyl itaconate) to study the intracellular functions of itaconate. So far, studies have shown that (1) native and derivatized itaconate inhibits SDH, a component of both the TCA cycle and the Complex II of the ETC [38-40], consequently impairing immune activation (e.g., the HIF-1α-IL-1β axis) [39] and viral replication [40,41]; (2) activates the anti-inflammatory nuclear factor erythroid 2-related factor 2 (NRF2; also known as NFE2L2) pathway via alkylation of the KEAP1 protein [42,43]; and (3) regulates the translation of IκBζ and the subsequent activation of the cyclic AMP-dependent transcription factor (ATF3) albeit without affecting the primary transcriptional responses to LPS stimulation [44]. Collectively, previous studies have highlighted the immunosuppressive properties of itaconate and suggested that itaconate is an integral part of a negative-feedback loop in toll-like receptor (TLR)-mediated immune activation in immune cells [42]. Of note, the cellular response to itaconate may differ from cell type to cell type and also depend on the type of stimulation, as studies showed that endogenous itaconate does not induce NRF2 activation in neurons upon viral infection [40]. So far, most of the analysis on the immunosuppressive effect of itaconate has been performed in LPS-activated macrophages, and we do not know whether itaconate has the same impact on immune signaling pathways in other cell types and/or with different stimuli. The most studied itaconate derivative is dimethyl itaconate (DMI), which is more electrophilic than the native form of itaconate. It is still unclear whether the native itaconate acts in the same way as its more electrophilic derivatives and deserves further investigations in the future.

3. Iso-Citrate

As mentioned above, iso-citrate is formed in the TCA cycle by the isomerization of citrate catalyzed by aconitase. Studies have demonstrated an increase in citrate and a decrease in isocitrate in LPS-activated pro-inflammatory macrophages [28,33]. Furthermore, pro-inflammatory macrophages downregulate iso-citrate dehydrogenase (IDH), resulting in an increased iso-citrate:α-ketoglutarate ratio. Pro-inflammatory dendritic cells (DCs) and macrophages show increased glycolytic flux and a break in the TCA cycle, where pyruvate derived from glucose feeds into the TCA cycle but cannot continue beyond...
citrate/isocitrate. [30,45,46]. Generally, the cytosolic isoenzyme IDH1 is suppressed in cells activated by pro-inflammatory stimuli [30,47]. In glucose-deprived conditions, IDH1 mRNA expression is increased in pro-inflammatory macrophages [30,48]. This may explain why the production of NO and ROS is decreased in glucose-deprived cells. So far, the immunological roles of cytosolic and mitochondrial iso-citrate remain elusive and deserve future investigations.

4. α-Ketoglutarate

α-Ketoglutarate is formed in the TCA cycle by oxidative decarboxylation of iso-citrate catalyzed by IDH. α-Ketoglutarate is involved in various metabolic pathways [49-53]. In humans, IDH exists in three isoforms: IDH1, -2, and -3. IDH1 acts in the cytoplasm and, thus, outside the context of TCA, while IDH2 and -3, as part of the TCA cycle, are found within the mitochondrial matrix [54]. α-Ketoglutarate can also be generated from glutamine and glutamate by deamination to feed into the TCA cycle [55,56], whereas α-ketoglutarate can conversely serve as a precursor of glutamine, which is a nutritionally semi-essential amino acid [57]. Previous studies have identified immunosuppressive roles for α-ketoglutarate. Interleukin-4 (IL-4)-induced anti-inflammatory macrophages have been shown to accumulate the metabolite α-ketoglutarate [58]. It was also found that α-ketoglutarate suppresses the activation of pro-inflammatory macrophages (e.g., IL-1β expression) and supports endotoxin tolerance after activation [26,59]. α-Ketoglutarate regulates the pro-inflammatory NF-κB signaling by stimulating prolyl hydroxylase (PHD; a family of α-ketoglutarate-dependent dioxygenases [α-KGDD]). PHD1 inactivates IKK-β kinase via hydroxylation of Pro191, which, in turn, phosphorylates IκB-α, activating NF-κB [57,60]. α-Ketoglutarate inhibits stabilization of hypoxia-induced factor (HIF)-1α, a transcription factor inducing expression of immune-related genes (e.g., pro-inflammatory cytokines [61], glycolytic enzymes, and glucose transporters [62-65]) by donating an electron to HIF-specific PHD for prolyl hydroxylation leading to the degradation of HIF-1α [28,53,58,62,66-70]. In line with this, reduced levels of α-ketoglutarate were found to abolish PHD activity [16,53,69,71,72]. Besides, α-ketoglutarate is an important co-factor for the α-KGDD family of Jumonji-C-domain-containing histone demethylases (JMJDs) and the ten-eleven translocation (TET) proteins, which are respectively involved in histone and DNA demethylation [26,57,59,73-79]. Of note, histone demethylation is also associated with HIF-1α degradation [78,80]. α-Ketoglutarate facilitates macrophage polarization also via induction of fatty acid oxidation [78,81]. In addition, α-ketoglutarate produced by glutaminolysis regulates polarization of macrophages toward anti-inflammatory phenotypes, e. g., via JMJD3-mediated epigenetic changes [26,57,59,78]. Of note, glutamine anaplerosis (replenishing of TCA cycle intermediates from glutamate) represents an important metabolic module governing the polarization of macrophages towards an anti-inflammatory phenotype, e.g., in response to IL-4 [26,45,79,82]. Like most of the TCA cycle intermediates, α-ketoglutarate is transported from the mitochondrial matrix to the cytoplasm and vice versa. It crosses the outer mitochondrial membrane through the voltage-dependent anion channel (VDAC), and the inner mitochondrial membrane through the α-ketoglutarate/malate antiporter [57,83]. Obviously, α-ketoglutarate leaking from dys-functioning mitochondria may exert similar anti-inflammatory functions as mitochondrial α-ketoglutarate transported into the cytosol.

5. Succinyl-CoA

Succinyl-CoA is formed by the decarboxylation of α-ketoglutarate catalyzed by α-ketoglutarate dehydrogenase (α-KGDH), a rate-limiting metabolic enzyme in the flux of the TCA cycle [72,84]. α-KGDH is responsive and sensitive to the levels of ROS impairing its function [72,85]. Of note, the increased α-KGDH activity in LPS-activated macrophages has been shown to limit the production of anti-inflammatory cytokine IL-10 [59,72]. An
increase of cytosolic calcium leading to rapid mitochondrial acidification promotes α-KGDH activity, boosting NADH production and oxidative metabolism [72,86,87]. Succinyl-CoA accumulation can result in lysine succinylation of cellular proteins [28,88,89]. This post-translational modification (PTM) induces a 100-Da change in mass and masks the positive charge of the lysine side chain, likely resulting in a significant conformational change in the target protein [90]. While succinylation is largely considered to occur spontaneously, desuccinylation is at least partly enzymatic, e.g., via mitochondrial sirtuin 5 (SIRT5) [91]. LPS induces succinylation, which impacts macrophage function. LPS-induced hyper-succinylation of lysine 311 on pyruvate kinase M2 (PKM2), a key glycolytic enzyme interacting with HIF-1α and regulating aerobic glycolysis in macrophages, inhibits its pyruvate kinase activity by promoting its tetramer-to-dimer transition and induces IL-1β secretion [58,90,92,93]. LPS decreases the expression of the desuccinylase SIRT5 [28,78]. SIRT5 desuccinylates various metabolic enzymes, including carbamoyl phosphate synthase 1 [78,94], SDH, PDH [78,90], acyl-CoA oxidase 1 [78,95], 3-hydroxy-3-methylglutaryl-CoA synthase 2 [78,96]. SIRT5 also desuccinylates PKM2 to prevent its entry into the nucleus and the formation of a HIF-1α/PKM2 complex [92]. Of note, the importance of this mechanism was highlighted by elevated levels of IL-1β in SIRT5-deficient mice examined in a colitis model [78,92]. Dysregulated succinate metabolism can also result in the accumulation of succinyl-CoA and lysine succinylation, a recently identified PTM [26,28,90]. Succinylation of certain proteins is found to drive immunosuppression in pro-inflammatory macrophages. Thus, the inflammatory effects of succinylation may be context-dependent and inducing various immunologic responses [28,58,97].

6. Succinate

Succinate is formed in the TCA cycle via the hydrolytic release of coenzyme A (CoA) catalyzed by succinyl-CoA synthetase. Alternatively, succinate is generated through the gamma-aminobutyric acid (GABA) shunt (a bypass of the TCA cycle, in which glutamine is used for the synthesis of glutamate, GABA, succinic semialdehyde, and eventually succinate) [28,62]. Succinate can be transported from the mitochondria to the cytosol by the dicarboxylic acid transporter. Succinate has been identified as an important metabolite in both host and microbial processes. Succinate accumulates in certain pathophysiological situations, particularly in areas of inflammation and metabolic stress [98,99]. Several studies have indicated its role of succinate in various cellular processes, such as epigenetic regulation, tumorigenesis, signal transduction, inflammation, and paracrine modulation [34,88,100,101] and have identified succinate as a metabolic signal governing local stress, tissue damage, and immunologic danger [28,102-105].

Succinate has emerged as a key player in macrophage activation [26,28,103,106]. Succinate is a highly accumulated metabolite in macrophages in response to LPS stimulation, largely depending on glutamine anaplerosis and immunometabolic reprogramming [26,28,99,106]. LPS-treated macrophages undergo a metabolic switch from oxidative phosphorylation to glycolysis, lowering the activity of the TCA cycle [107]. Of note, activated immune cells display the so-called immunologic “Warburg effect”, a term originating from cancer biology. This term describes the phenomenon that immune activation is linked to glycolysis, as cancer cells favor glycolytic metabolism [108,109], implying that immune activation requires and promotes glycolysis in a bidirectional relationship. The metabolic switch is important for the survival of immune cells at sites of inflammation, where oxygen levels are low. In this process, HIF-1α enables the cells to adapt to a low oxygen environment as a key oxygen sensor by regulating cellular responses [99,110,111]. Succinate may be accumulated following LPS treatment through SDH inhibition and post-translationally modify cellular proteins, e.g., glycolytic enzymes, including malate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [28,82,111,112]. Notably, a high succinate/α-ketoglutarate ratio was linked to the pro-inflammatory phenotype, whereas a low ratio was associated with macrophage polarization towards an
anti-inflammatory phenotype [59,78]. As PHD dehydroxylation converts oxygen and α-ketoglutarate to succinate and CO2, high levels of succinate can slow PHDs through product inhibition [99,113]. Importantly, the balance between succinate and α-ketoglutarate levels intracellularly regulate members of α-KGDDs involved in epigenome remodeling and innate immune memory [26,57,59,114]. Like PHDs, α-KGDDs undergo competitive inhibition by succinate, and so the ratio of α-ketoglutarate to succinate can often be a key determinant of their enzymatic activity [26,59]. LPS-induced succinate can enhance the pro-inflammatory activity in macrophages by promoting the expression of the key pro-inflammatory cytokine IL-1β [28,107,111,115-117]. In effect, succinate behaves as a danger signal or alarmin to sustain the production of IL-1β by promoting the binding of HIF-1α to a hypoxia-response element (HRE) in its promoter [26,28,78,104,107,111-119]. HIF-1α down-regulates oxidative phosphorylation by inducing PDH kinase 1 (PDK1) and 3 (PDK3), both of which in turn also inactivate PHD, allowing for further stabilization of HIF-1α [82,120-123]. It has been demonstrated that pharmacologic inhibition of SDH or RNA interference of subunit B of SDH, induces HIF-1α stabilization in a ROS-dependent manner [34,124]. More recently, succinate oxidation in LPS-activated macrophages was shown to inhibit PHD activity indirectly via mitochondrial ROS resulting in HIF-1α stabilization and IL-1β production [26,106]. This effect is blocked by α-ketoglutarate, the substrate for PHD that generates succinate as a by-product in HIF-1α hydroxylation [28,125]. Succinate also undergoes oxidation by SDH to drive mitochondrial ROS generation from the Complex I [26,28,106]. Consequently, mitochondrial ROS production increases, subsequently stabilizing HIF-1α, the driver of additional pro-inflammatory responses in macrophages [28,58,106,126].

In DCs, succinate triggers intracellular calcium mobilization, induces migratory responses, and acts in synergy with TLR ligands to induce the production of pro-inflammatory cytokines [78,105]. Indeed, IL-1β expression is enhanced in murine bone marrow-derived DCs treated with succinate and LPS simultaneously [105,111]. Succinate was found to act in synergy with the TLR3 ligand poly(I:C) and the TLR7 ligand imiquimod, increasing TNF-α production [34,127]. Succinate also increases the capacity of DCs to present antigens to T cells and induce adaptive immune responses, which may further exacerbate inflammation [111,128]. When DCs are primed with succinate and antigen simultaneously, antigen-specific T cell activation is elevated, as measured by increased tumor necrosis factor (TNF)-α and interferon (IFN)-γ production from these cells [111,129]. Interestingly, HIF-1α-deficient DCs show impaired ability to activate T cells [130], suggesting that this transcription factor is important for T cell polarization and activation [34]. In the adaptive compartment, HIF-1α activation favors the differentiation of T lymphocytes into pro-inflammatory Th17 cells and attenuates regulatory T (Treg) cell development [34,131]. An increase in succinate caused by a loss of Complex III was also shown in Tregs to inhibit TET activity, which is necessary to maintain immune regulatory gene expression and suppressive function [78,132]. Succinate can induce the activation of hematopoietic stem cells, and regulate their proliferation, migration, and apoptosis in vitro, along with increasing the secretion of inflammatory cytokines, such as IL-6 and TNF-α [88,133,134]. Succinate also accumulates in hypoxia during ischemia-reperfusion injury, where its accumulation and oxidation control ROS production and contributed to the severity of tissue injury [78,104,135,136]. Similarly, succinate is also associated with inflammatory diseases [58,137]. Elevated amounts of circulating succinate occur in some physiological conditions, such as endurance exercise [103,138] and in certain pathologies, including inflammatory bowel disease [139-148], sepsis [28,132,149], hypertension, ischemic heart disease [103,150] type 2 diabetes mellitus [103,151,152] and obesity [103,151,153]. Numerous studies have identified tissue-specific and systemic effects of succinate as a pro-inflammatory mediator [99,100,105,152]. During inflammation, IL-37 restores cellular metabolism by reducing succinate, inhibiting mTOR, and activating AMPK [154]. The role of succinate as a signaling molecule in inflammation and disease has been discussed in more detail elsewhere [28,34,155].
As succinate is not membrane-penetrant, researchers generated a succinate derivate, which is cell-permeable. Using diethyl succinate, they increased the intracellular levels of succinate [58]. However, diethyl succinate appears to be immunosuppressive similar to DMI and dimethyl fumarate (DMF), suppressing LPS-induced pro-inflammatory cytokine secretion, gene and marker expression (such as IL-1β, IL-6, TNF-α, nitric oxide, CD40, CD86) in bone marrow-derived macrophages [58]. Another cell-permeable derivate of 4C organic compound, which was used to study the intracellular function of succinate was dimethyl malonate (DMM). DMM is an inhibitor for SDH, which increases intracellular levels of succinate in macrophages [58,106]. Here again, DMM showed a dose-dependent inhibition of inflammatory mediators IL-6, TNF-α, and NO. This may suggest a role for intracellular succinate to inhibit inflammatory responses, as SDH activity is described to be altered in pro-inflammatory macrophages, thus leading to succinate accumulation. We note that derivatized TCA cycle intermediates generally exhibit strong immunosuppressive features. The derivatization of TCA cycle intermediates may drastically increase the electrophilicity of the molecule, and the native and derivative may act via different chemical reactions [44,156,157]. Overall, studies have shown that endogenous succinate promotes immune activation. Obviously, succinate leaking from dysfunctioning mitochondria may exert similar pro-inflammatory functions as mitochondrial succinate transported into the cytosol.

7. Fumarate

Fumarate is formed in the TCA cycle by the SDH-catalyzed dehydrogenation of succinate [98,111,156,158]. Activation of innate immune cells, such as macrophages and monocytes, with pro-inflammatory stimuli (e.g., LPS, IFN-γ) leads to remodeling of the TCA cycle and intracellular accumulation of fumarate [28,39,118,159-161]. LPS-activated macrophages show a substantial increase in flux through the induction of aspartate-arginosuccinate shunt, which fuels and maintains the TCA cycle flux [45, 160]. Furthermore, being connected to the TCA cycle at fumarate, the induced aspartate-arginosuccinate shunt causes the accumulation of fumarate in activated macrophages [160]. Interestingly, the inhibition of the aspartate-arginosuccinate shunt leads to the downregulation of the pro-inflammatory mediators, including NO and IL-6, along with suppression of the ‘immunologic Warburg effect’ in activated macrophages [160]. Therefore, replenishing fumarate seems to be important for metabolic reprogramming of macrophages during inflammation [160]. The elevated cytokine response in these cells is linked to an increase in the amount of fumarate sufficient to drive the response by activating HIF-1α [33,162]. The accumulation of fumarate by inhibiting fumarate hydratase (FH; also known as fumarase) with FHIN1 impairs cell death and reduces the formation of gasdermin D, the executioner of pyroptosis [159]. An in vivo-compatible FH inhibitor, FHIN2, elevates FH levels in vivo and reduces IL-1β, indicating that fumarate inhibits pyroptosis in vivo [159]. Loss of function of FH in cancers increases fumarate levels leading to elevated accumulation of NRF2 [163,164]. Fumarate can attenuate autoimmune diseases, in part, through modulation of DC maturation and antigen-presenting capacity [165-168]. In general, fumarate is considered anti-inflammatory. Like other TCA cycle metabolites, fumarate is a cell-impermeable polar molecule. Therefore, researchers developed fumarate derivatives with increased intracellular penetrance to study immunological features of fumarate. Of note, the stable derivative of fumarate, DMF, is known to be a strong immunosuppressive. DMF is a leading oral therapy for multiple sclerosis (Trade name: Tecfidera®). DMF is more electrophilic than fumarate and other structurally similar metabolites, such as DMI, and itaconate [44]. Therefore, whether the native fumarate has a similar effect in vivo and in vitro has yet to be determined [156,157]. Whereas the precise mechanism of immunosuppression has remained elusive, increasing evidence indicates that the critical mechanism of DMF is related to its high electrophilicity, which allows DMF to modify proteins by reacting with cysteines via an electrophilic (Michael-type) addition [169,170], impacting the
function of proteins. Several groups have proposed that DMF stimulates an antioxidant response by modifying cysteine residues in the NRF2-KEAP1 complex, which is a major electrophile response pathway in mammals [156,163,171-175]. The transcription factor NRF2 has been shown to alleviate inflammation by inducing heme oxygenase-1 (HO-1), which potentially increases IRG1 and downregulates TNF-α expression [175-179]. An Nrf2 deficiency causes an exacerbation of inflammation in a variety of murine models, such as sepsis, pleurisy, and emphysema [180-183], and also causes autoimmune phenotypes in some murine strains [184,185]. GAPDH has been hypothesized to play a key role in the mechanism of action of DMF [186]. Through modification of the active site cysteine (Cys152 in humans) and resulting in inactivation of GAPDH, DMF has been proposed to downregulate glycolysis and ultimately mediate its anti-inflammatory effects observed in B lymphocytes of DMF-treated multiple sclerosis patients. However, a recent study suggested that this mechanism does not have the primary role in DMF-mediated immunosuppression [159].

Nonetheless, the exact role of intracellular fumarate during inflammation is yet to be investigated [160]. Outside mitochondria, succinate and fumarate can inhibit certain demethylation reactions. Accumulation of succinate and fumarate leads to the inhibition of DNA demethylases and KDMs via product inhibition. Accordingly, fumarate accumulation (e.g., derived from glutaminolysis) was shown to inhibit KDM5 histone demethylases, altering H3K4 methylation at the promoters of pro-inflammatory cytokines, such as Tnfa and Il6 [33,79,80,156,162,187-191] and regulating the chromatin-modifying activities of histone acetyltransferases or deacetylases by altering their post-translational lysine methylation status [189]. Fumarate induces epigenetic changes in macrophages that are associated with trained immunity [80,188]. Interestingly, exposing monocytes to fumarate, but not succinate or malate, for 24 h recapitulated the trained macrophage phenotype in terms of augmented pro-inflammatory cytokine production capacity. This was accompanied by an enrichment of H3K4me3 on the promoters of the cytokine genes, due to a direct inhibitory effect of fumarate on the KDM5 family of histone demethylases, which are responsible for demethylation of H3K4 [80,189,192]. This effect could partly be restored by the addition of α-ketoglutarate [189-192]. The striking elevation of succinate and fumarate induced by the metabolic rewiring of trained macrophages, therefore, represents a plausible mechanism underlying the integration of immunometabolic and epigenetic programs in trained immunity [76,189]. Fumarate degradation is detrimental to the host and abrogates trained immunity, promoting recurrent infections [188].

8. Malate and Oxaloacetate

L-malate is formed by the hydration of fumarate catalyzed by FH. In the last reaction of the citric acid cycle, L-malate dehydrogenase oxidizes L-malate to oxaloacetate. Not much is known about the immunological role of intracellular L-malate and oxaloacetate, although the activation of macrophages with LPS results in increased levels of L-malate [28,61]. Oxaloacetate serves as a strong inhibitor of SDH, thereby limiting post-ischemic oxidation of succinate. It would be worth examining whether the endogenously formed oxaloacetate conveys protection through reduced SDH activity during reperfusion [193]. Future studies are needed to determine the immunological roles of L-malate and oxaloacetate during a mitochondrial disruption.
Discussion

This review has provided insights into the immunological roles of TCA cycle intermediates that may leak from functioning mitochondria along with other mitochondrial danger molecules and regulate the cellular immunity. In cells with mitochondrial stress, TCA cycle metabolites, such as citrate, itaconate, succinate, fumarate, L-malate may accumulate despite decreased mitochondrial respiration and link cellular metabolism to innate leukocyte responses [28,58,61,118,156,160,161,194]. Activation of immune cells leads to the remodeling of the TCA cycle via a process called the 'immunologic Warburg effect'. The TCA cycle intermediates citrate, α-ketoglutarate, succinate, and fumarate regulate inflammatory gene expression [26,33,79,80,156,162,187-191]. Innate immune cells use ROS as a key signaling and functional molecule during inflammation. TCA cycle intermediates such as succinate, citrate, fumarate, and itaconate are thereby important regulators of the production of ROS [162]. Acetyl-CoA, succinate, and fumarate may also regulate the innate immune responses by post-translationally modifying proteins via acetylation, succinylation, and succination [79,195]. Certain metabolites such as acetyl-CoA, succinate, NAD+, and α-ketoglutarate can serve as co-factors for epigenetic enzymes, thus potentiating innate immune memory [36,191]. It is important to note the balancing of succinate, α-ketoglutarate, and fumarate levels in macrophages can alter the epigenetic landscape of the cell, profoundly impacting macrophage polarization and innate immune memory [26,76,156,196,197]. Overall, studies have shown that citrate and succinate have pro-inflammatory properties, whereas itaconate, α-ketoglutarate, and fumarate are linked more with immunosuppressive roles (Figure 3). Interestingly, most of the latter metabolites are upregulated during immune activation, indicating that they balance immune activation and suppression. The immunological roles of some TCA cycle metabolites, such as iso-citrate, L-malate, oxaloacetate, are only partially understood and deserve further investigation in the future (Figure 3).
Author Contributions: Conceptualization, J.-H.B.; writing, I.C, H.S., J.-H.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bhargava, P.; Schnellmann, R.G. Mitochondrial energetics in the kidney. Nat Rev Nephrol 2017, doi:10.1038/nrneph.2017.107.
2. Arnould, D.; Soares, F.; Tattoli, I.; Girardin, S.E. Mitochondria in innate immunity. EMBO Rep 2011, 12, 901-910, doi:10.1038/embor.2011.157.
3. West, A.P.; Khoury-Hanold, W.; Staron, M.; Tal, M.C.; Pineda, C.M.; Lang, S.M.; Bestwick, M.; Duguay, B.A.; Raimundo, N.; MacDuff, D.A., et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature 2015, 520, 553-557, doi:10.1038/nature14156.
4. White, M.J.; McArthur, K.; Metcalf, D.; Lane, R.M.; Cambier, J.C.; Herold, M.J.; van Delft, M.F.; Bedoui, S.; Lessene, G.; Ritchie, M.E., et al. Apoptotic caspases suppress mtDNA-induced STING-mediated type I IFN production. Cell 2014, 159, 1549-1562, doi:10.1016/j.cell.2014.11.036.
5. Gutteridge, J.M. Free radicals in disease processes: a compilation of cause and consequence. Free Radic Res Commun 1993, 19, 141-158.
6. Ray, P.D.; Huang, B.W.; Tsuji, Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012, 24, 981-990, doi:10.1016/j.cellsig.2012.01.008.
7. Holmstrom, K.M.; Finkel, T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol 2014, 15, 411-421, doi:10.1038/nrm3801.
8. Chan, Y.K.; Gack, M.U. Viral evasion of intracellular DNA and RNA sensing. Nat Rev Microbiol 2016, 14, 360-373, doi:10.1038/nrmicro.2016.43.
9. Sun, Q.; Sun, L.; Liu, H.H.; Chen, X.; Seth, R.B.; Forman, J.; Chen, Z.J. The specific and essential role of MAVS in antiviral innate immune responses. Immunity 2006, 24, 633-642, doi:10.1016/j.immuni.2006.04.004.
10. Sun, L.; Wu, J.; Du, F.; Chen, X.; Chen, Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339, 786-791, doi:10.1126/science.1232458.
11. Ablasser, A.; Hemmerling, I.; Schmidt-Burgeg, J.L.; Behrendt, R.; Roers, A.; Horming, V. TREX1 deficiency triggers cell-autonomous immunity in a GAS-dependent manner. J Immunol 2014, 192, 5993-5997, doi:10.4049/jimmunol.1400737.
12. Cai, X.; Chiu, Y.H.; Chen, Z.J. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 2014, 54, 289-296, doi:10.1016/j.molcel.2014.03.040.
13. Lee, H.; Fenster, R.J.; Pineda, S.S.; Gibbs, W.S.; Mohammad, S.; Davila-Velderrain, J.; Garcia, F.J.; Therrien, M.; Novis, H.S.; Gao, F., et al. Cell Type-Specific Transcriptionomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune Activation. Neuron 2020, 107, 891-908.e898, doi:10.1016/j.neuron.2020.06.021.
14. West, A.P. Mitochondrial dysfunction as a trigger of innate immune responses and inflammation. Toxicology 2017, doi:10.1016/j.tox.2017.07.016.
15. Baek, J.H.; Gomez, I.G.; Wada, Y.; Roach, A.; Mahad, D.; Duffield, J.S. Deletion of the Mitochondrial Complex-IV Cofactor Heme A:Farnesyltransferase Causes Focal Segmental Glomerulosclerosis and Interferon Response. Am J Pathol 2018, 188, 2745-2762, doi:10.1016/j.ajpath.2018.08.018.
16. Martinez-Reyes, I.; Chandel, N.S. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun 2020, 11, 102, doi:10.1038/s41467-019-13668-3.
17. Lee, J.V.; Carrer, A.; Shah, S.; Snyder, N.W.; Wei, S.; Venneti, S.; Worth, A.J.; Yuan, Z.F.; Lim, H.W.; Liu, S., et al. Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab 2014, 20, 306-319, doi:10.1016/j.cmet.2014.06.004.
18. Lozoya, O.A.; Wang, T.; Grenet, D.; Wolfgang, T.C.; Sobhany, M.; Canini da Silva, D.; Riadi, G.; Chandel, N.; Woychik, R.P.; Santos, J.H. Mitochondrial acetyl-CoA reversibly regulates locus-specific histone acetylation and gene expression. Life Sci Alliance 2019, 2, doi:10.26508/lsa.201800228.
19. Kurdistani, S.K.; Grunstein, M. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 2003, 4, 571-578, doi:10.1038/nrm1075.
20. Palma, L.; Amatori, S.; Cruz Chamorro, I.; Fanelli, M.; Magnani, M. Promoter-specific relevance of histone modifications induced by dexamethasone during the regulation of pro-inflammatory mediators. Biochim Biophys Acta 2013, 1834, 1735-1743, doi:10.1016/j.bbagrm.2013.05.007.
21. Wellen, K.E.; Hatzivassiliou, G.; Sachdeva, U.M.; Bui, T.V.; Cross, J.R.; Thompson, C.B. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009, 324, 1076-1080, doi:10.1126/science.1164997.
22. Feng, D.; Sangster-Guity, N.; Stone, R.; Korczewniska, J.; Manc, M.E.; Fitzgerald-Bocarsly, P.; Barnes, B.J. Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. J Immunol 2010, 185, 6003-6012, doi:10.4049/jimmunol.1000482.
23. Hu, L.; Yu, Y.; Huang, H.; Fan, H.; Yin, C.; Li, K.; Fulton, D.J.; Chen, F. Epigenetic Regulation of Interleukin 6 by Histone
decay of histone
d2016, 7, 696, doi:10.3389/fimmu.2016.00696.
24. Moores, R.C.; Brilha, S.; Schutgens, F.; Elkington, P.T.; Friedland, J.S. Epigenetic Regulation of Matrix Metalloproteinase-1
and 3 Expression in Mycobacterium tuberculosis Infection. Front Immunol 2017, 8, 602, doi:10.3389/fimmu.2017.00602.
25. Lu, J.; Sun, H.; Wang, X.; Liu, C.; Xu, X.; Li, F.; Huang, B. Interleukin-12 p40 promoter activity is regulated by the reversible
caylation mediated by HDAC1 and p300. Cytokine 2005, 31, 46-51, doi:10.1016/j.cyt.2005.03.001.
26. Ryan, D.G.; O’Neill, L.A.J. Krebs Cycle Reborn in Macrophage Immunometabolism. Annu Rev Immunol 2020, 38, 289-313,
doi:10.1146/annurev-immunol-081619-104850.
27. Wang, B.; Tao, Y.H.; Inoue, M.; Hao, R.; Lai, C.H.; Chen, D.; McDonald, S.L.; Choi, M.C.; Wang, Q.; Shinohara, M.L., et al.
Microtubule acetylation amplifies p38 kinase signalling and anti-inflammatory IL-10 production. Nat Commun 2014, 5,
3479, doi:10.1038/ncomms4799.
28. Tannahill, G.M.; Curtis, A.M.; Adamik, J.; Palsson-Mc Dermott, E.M.; McGettrick, A.F.; Goel, G.; Frezza, C.; Bernard, N.J.;
Kelly, B.; Foley, N.H., et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 2013, 496, 238-
242, doi:10.1038/nature13986.
29. Infantino, V.; Iacobazzi, V.; Menga, A.; Avantaggiati, M.L.; Palmieri, F. A key role of the mitochondrial citrate carrier
(SLC25A1) in TNFα- and IFNγ-triggered inflammation. Biochim Biophys Acta 2014, 1839, 1217-1225,
doi:10.1016/j.bbagrm.2014.07.013.
30. Williams, N.C.; O’Neill, L.A.J. A Role for the Krebs Cycle Intermediate Citrate in Metabolic Reprogramming in Innate
Immunity and Inflammation. Front Immunol 2018, 9, 141, doi:10.3389/fimmu.2018.00141.
31. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
32. Taylor, W.M.; Halperin, M.L. Regulation of pyruvate dehydrogenase in muscle. Inhibition by citrate. J Biol Chem 1973, 248,
6080-6083.
33. Infantino, V.; Convertini, P.; Cucci, L.; Panaro, M.A.; Di Noia, M.A.; Calvello, R.; Palmieri, F.; Iacobazzi, V. The mitochondrial
citrate carrier: a new player in inflammation. Biochem Biophys Res Commun 2013, 440, 105-111, doi:10.1016/j.bbrc.2013.09.037.
34. Daniels, B.P.; Kofman, S.B.; Smith, J.R.; Norris, G.T.; Snyder, A.G.; Kolb, J.P.; Gao, X.; Locasale, J.W.; Martinez, J.; Gale, M.,
Jr., et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 2018, 556, 3479,
doi:10.1038/s41586-018-0052-z.
35. Infantino, V.; Iacobazzi, V.; Palmieri, F.; Menga, A. ATP-citrate lyase is essential for macrophage inflammatory response.
Biochem Biophys Res Commun 2013, 440, 105-111, doi:10.1016/j.bbrc.2013.09.037.
36. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
37. Infantino, V.; Convertini, P.; Cucci, L.; Panaro, M.A.; Di Noia, M.A.; Calvello, R.; Palmieri, F.; Iacobazzi, V. The mitochondrial
citrate carrier: a new player in inflammation. Biochem Biophys Res Commun 2013, 440, 105-111, doi:10.1016/j.bbrc.2013.09.037.
38. Daniels, B.P.; Kofman, S.B.; Smith, J.R.; Norris, G.T.; Snyder, A.G.; Kolb, J.P.; Gao, X.; Locasale, J.W.; Martinez, J.; Gale, M.,
Jr., et al. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature 2018, 556, 3479,
doi:10.1038/s41586-018-0052-z.
39. Williams, N.C.; O’Neill, L.A.J. A Role for the Krebs Cycle Intermediate Citrate in Metabolic Reprogramming in Innate
Immunity and Inflammation. Front Immunol 2018, 9, 141, doi:10.3389/fimmu.2018.00141.
40. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
41. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
42. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
43. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
44. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
45. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
46. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
47. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
48. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
49. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
50. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
51. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
52. Hillar, M.; Lott, V.; Lennox, B. Correlation of the effects of citric acid cycle metabolites on succinate oxidation by rat liver
mitochondria and submitochondrial particles. J Bioenerg 1975, 7, 1-16, doi:10.1007/BF01558459.
47. Haseeb, A.; Makki, M.S.; Haqqi, T.M. Modulation of ten-eleven translocation 1 (TET1), Isocitrate Dehydrogenase (IDH) expression, α-Ketoglutarate (α-KG), and DNA hydroxymethylation levels by interleukin-1β in primary human chondrocytes. J Biol Chem 2014, 289, 6877-6885, doi:10.1074/jbc.M113.512269.

48. Palmieri, E.M.; Spera, I.; Menga, A.; Infantino, V.; Porcelli, V.; Iacobazzi, V.; Pietri, C.L.; Hooper, D.C.; Palmieri, F.; Castegna, A. Acetylation of human mitochondrial citrate carrier modulates mitochondrial citrate/malate exchange activity to sustain NADPH production during macrophage activation. Biochim Biophys Acta 2015, 1847, 729-738, doi:10.1016/j.bbabio.2015.04.009.

49. Bruns, G.A.; Eisenman, R.E.; Gerald, P.S. Human mitochondrial NADP-dependent isocitrate dehydrogenase in man-mouse somatic cell hybrids. Cytogenet Cell Genet 1976, 17, 200-211, doi:10.1159/000130713.

50. Shimizu, N.; Gries, R.E.; Kucherlapati, R.S.; Shimizu, Y.; Rudie, F.H. Somatic cell genetic assignment of the human gene for mitochondrial NADP-linked isocitrate dehydrogenase to the long arm of chromosome 15. Somatic Cell Genet 1977, 3, 47-60, doi:10.1007/BF01550986.

51. Geisbrecht, B.V.; Gould, S.J. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem 1999, 274, 30527-30533, doi:10.1074/jbc.274.43.30527.

52. Corpas, F.J.; Barroso, J.B.; Sandalio, L.M.; Palma, J.M.; Lupiáñez, J.A.; del Rio LA. Peroxisomal NADP-Dependent Isocitrate Dehydrogenase. Characterization and Activity Regulation during Natural Senescence. Plant Physiol 1999, 121, 921-928, doi:10.1104/pp.121.3.921.

53. Xiang, S.; Gu, H.; Jin, L.; Thorne, R.F.; Zhang, X.D.; Wu, M. LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect. Proc Natl Acad Sci U S A 2015, 112, 14005-14010, doi:10.1073/pnas.1508556112.

54. Tommasini-Ghelfi, S.; Murman, K.; Kouri, F.M.; Mahajan, A.S.; May, J.K.; Stegh, A.H. Cancer-associated IDH1 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis. Cancer Res 2009, 69, 3526-3531, doi:10.1158/0008-5472.CAN-08-2544.

55. Abla, H.; Sollazzo, M.; Gasparre, G.; Iommarini, L.; Porcelli, A.M. The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit? Semin Cell Dev Biol 2020, 98, 26-33, doi:10.1016/j.semcdb.2019.05.031.

56. Corfas, G.; Barroso, J.B.; Sandalio, L.M.; Palma, J.M.; Lupiáñez, J.A.; del Rio LA. Peroxisomal NADP-Dependent Isocitrate Dehydrogenase. Characterization and Activity Regulation during Natural Senescence. Plant Physiol 1999, 121, 921-928, doi:10.1104/pp.121.3.921.

57. Chen, L.; Chen, X.W.; Huang, X.; Song, B.L.; Wang, Y. Regulation of glucose and lipid metabolism in health and disease. Sci China Life Sci 2019, 62, 1420-1458, doi:10.1007/s11427-019-1563-3.

58. Song, W.; Li, D.; Tao, L.; Luo, Q.; Chen, L. Solute carrier transporters: the metabolic gatekeepers of immune cells. Acta Pharm Sin B 2020, 10, 61-78, doi:10.1016/j.apsb.2019.12.006.

59. Abla, H.; Sollazzo, M.; Gasparre, G.; Iommarini, L.; Porcelli, A.M. The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit? Semin Cell Dev Biol 2020, 98, 26-33, doi:10.1016/j.semcdb.2019.05.031.

60. Harber, K.J.; de Goede, K.E.; Verberk, S.G.S.; Meimister, E.; de Vries, H.E.; van Weeghel, M.; de Winther, M.P.J.; Van den Bosche, J. Scurface Is an Inflammation-Induced Immunoregulatory Metabolite in Macrophages. Metabolites 2020, 10, 399, doi:10.3390/metabo10090372.

61. Liu, P.S.; Wang, H.; Li, X.; Chao, T.; Teav, T.; Christen, S.; Di Conza, G.; Cheng, W.C.; Chou, C.H.; Vavakova, M., et al. α-Ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol 2017, 18, 985-994, doi:10.1038/nri.3796.

62. Cummins, E.P.; Berra, E.; Comerford, K.M.; Ginouves, A.; Fitzgerald, K.T.; Seeballuck, F.; Godson, C.; Nielsen, J.E.; Moynagh, P.; Fouysssegur, J., et al. Prolig hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 2006, 103, 18154-18159, doi:10.1073/pnas.0602235103.

63. Galván-Peña, S.; O'Neill, L.A. Metabolic reprogramming in macrophage polarization. Front Immunol 2019, 10, 1462, doi:10.3389/fimmu.2019.01462.

64. Viola, A.; Munari, F.; Sánchez-Rodríguez, R.; Scolaro, T.; Castegna, A. The Metabolic Signature of Macrophage Responses. Front Immunol 2019, 10, 462, doi:10.3389/fimmu.2019.01462.

65. Wang, T.; Liu, H.; Lian, G.; Zhang, S.Y.; Wang, X.; Jiang, C. HIF1α-Induced Glycolysis Metabolism Is Essential to the Activation of Inflammatory Macrophages. Mediators Inflamm 2017, 2017, 9029327, doi:10.1155/2017/9029327.

66. van Uden, P.; Kenneth, N.S.; Rocha, S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J 2008, 412, 477-484, doi:10.1042/BJ20080476.

67. Rius, J.; Guma, M.; Schachtzup, C.; Akassoglou, K.; Zinkernagel, A.S.; Nizet, V.; Johnson, R.S.; Haddad, G.G.; Karin, M. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453, 807-811, doi:10.1038/nature06905.

68. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Asaad, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360, 791-807, doi:10.1056/NEJMoa0808710.

69. Dang, L.; White, D.W.; Gross, S.; Bennett, B.D.; Bittenger, M.A.; Driggers, E.M.; Fantin, V.R.; Jang, H.G.; Jin, S.; Keenan, M.C., et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462, 739-744, doi:10.1038/nature08617.

70. Paschka, P.; Schlenk, R.F.; Gaedzick, V.I.; Habdank, M.; Krönke, J.; Buhlker, L.; Späth, D.; Kayser, S.; Zucknick, M.; Götzke, K., et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010, 28, 3636-3643, doi:10.1200/JCO.2010.28.3762.

71. MacKenzie, E.D.; Selak, M.A.; Tennant, D.A.; Payne, L.J.; Crosby, S.; Frederiksen, C.M.; Watson, D.G.; Gottlieb, E. Cells permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol 2007, 27, 3282-3289, doi:10.1128/MCB.01927-06.
95. Chen, X.F.; Tian, M.X.; Sun, R.Q.; Zhang, M.L.; Zhou, L.S.; Jin, L.; Chen, L.L.; Zhou, W.J.; Duan, K.L.; Chen, Y.J., et al. SIRT5

92. Wang, F.; Wang, K.; Xu, W.; Zhao, S.; Ye, D.; Wang, Y.; Xu, Y.; Zhou, L.; Chu, Y.; Zhang, C., et al. SIRT5 Desuccinylates and

91. Du, J.; Zhou, Y.; Su, X.; Yu, J.J.; Khan, S.; Jiang, H.; Kim, J.; Woo, J.; Kim, J.H.; Choi, B.H., et al. Sirt5 is a NAD-dependent

90. Park, J.; Chen, Y.; Tishkoff, D.X.; Peng, C.; Tan, M.; Dai, L.; Xie, Z.; Zhang, Y.; Zwaans, B.M.; Skinner, M.E., et al. SIRT5-

89. Zhang, Y.; Bharathi, S.S.; Rardin, M.J.; Lu, J.; Maringer, K.V.; Sims-Lucas, S.; Prochownik, E.V.; Gibson, B.W.; Goetzman,

88. Cho, E.H. Succinate as a Regulator of Hepatic Stellate Cells in Liver Fibrosis. Front Endocrinol (Lausanne) 2018, 9, 455,

87. Griffiths, E.J.; Rutter, G.A. Mitochondrial calcium as a key regulator of mitochondrial ATP production in mammalian cells.

86. Tretter, L.; Adam-Vizi, V. Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. Philos Trans R

83. Monné, M.; Miniero, D.V.; Iacobazzi, V.; Bisaccia, F.; Fiermonte, G. The mitochondrial oxoglutarate carrier: from identifi-

82. Palsson-McDermott, E.M.; O’Neill, L.A. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays

81. Littlewood-Evans, A.; Sarret, S.; Apfel, V.; Loesle, P.; Dawson, J.; Zhang, J.; Muller, A.; Tigani, B.; Kneuer, R.; Patel, S., et al.

80. Arts, R.J.; Novakovic, B.; Ter Horst, R.; Carvalho, A.; Bekkering, S.; Lachmandas, E.; Rodrigues, F.; Silvestre, R.; Cheng,

79. Peruzzotti-Jametti, L.; Pluchino, S. Targeting Mitochondrial Metabolism in Neuroinflammation: Towards a Therapy for

78. Zasłona, Z.; O’Neill, L.A.J. Cytokine-like Roles for Metabolites in Immunity. Mol Cell 2020, 78, 814-823, doi:10.1016/j.mol-

76. Xiao, M.; Yang, H.; Xu, W.; Ma, S.; Lin, H.; Zhu, H.; Liu, L.; Liu, Y.; Yang, C.; Xu, Y., et al. Inhibition of α-KG-dependent

75. He, Y.F.; Li, B.Z.; Li, Z.; Liu, P.; Wang, Y.; Tang, Q.; Ding, J.; Jia, Y.; Chen, Z.; Li, L., et al. Tet-mediated formation of 5-

74. Ito, S.; Shen, L.; Dai, Q.; Wu, S.C.; Collins, L.B.; Swenberg, J.A.; He, C.; Zhang, Y. Tet proteins can convert 5-methylcytosine

73. Tahiliani, M.; Koh, K.P.; Shen, Y.; Pastor, W.A.; Bandukwala, H.; Brudno, Y.; Agarwal, S.; Iyer, L.M.; Liu, D.R.; Aravind, L.,

72. Lio, C.J.; Huang, S.C. Circles of Life: linking metabolic and epigenetic cycles to immunity. Immunology 2020, 161, 165-174,

71. Bargiela, D.; Burr, S.P.; Chinnery, P.F. Mitochondria and Hypoxia: Metabolic Crosstalk in Cell-Fate Decisions. Trends Endo-

70. Majmundar, A.J.; Wong, W.J.; Simon, M.C. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010, 40, 294-309, doi:10.1016/j.molcel.2010.09.022.

69. Tietze, F.; Drabkin, L.J. The colorimetric determination of dehydrogenases. J Biol Chem 1955, 213, 321-337.

68. Beer, A.; Almqvist, E.S. Lysine desuccinylase SIRT5 binds to cardiolipin and regulates the electron transport chain. J Biol Chem 2017, 292, 10239-10249, doi:10.1074/jbc.M117.785022.

67. Park, J.; Chen, Y.; Tishkoff, D.X.; Peng, C.; Tan, M.; Dai, L.; Xie, Z.; Zhang, Y.; Zwaans, B.M.; Skinner, M.E., et al. SIRT5-

66. Nakagawa, T.; Lomb, D.J.; Haigis, M.C.; Guarente, L. SIRT5 Deacetylases carbamoyl phosphate synthetase 1 and regulates

65. Chen, X.F.; Tian, M.X.; Sun, R.Q.; Zhang, M.L.; Zhou, L.S.; Jin, L.; Chen, L.L.; Zhou, W.J.; Duan, K.L.; Chen, Y.J., et al. SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep 2018, 19, doi:10.15252/embr.201745124.

64. Major, F.; Gschwantler, S.; El-Agnaf, O.M. NAD-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 2012, 26, 1326-1338, doi:10.1101/gad.191056.112.

63. Monnè, M.; Miniero, D.V.; Iacobazzi, V.; Bisaccia, F.; Fiermonte, G. The mitochondrial oxoglutarate carrier: from identifi-

62. Monné, M.; Miniero, D.V.; Iacobazzi, V.; Bisaccia, F.; Fiermonte, G. The mitochondrial oxoglutarate carrier: from identifi-

61. Monnè, M.; Miniero, D.V.; Iacobazzi, V.; Bisaccia, F.; Fiermonte, G. The mitochondrial oxoglutarate carrier: from identifi-

60. Majmundar, A.J.; Wong, W.J.; Simon, M.C. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010, 40, 294-309, doi:10.1016/j.molcel.2010.09.022.
96. Rardin, M.J.; He, W.; Nishida, Y.; Newman, J.C.; Carrico, C.; Danielsen, S.R.; Guo, A.; Gut, P.; Sahu, A.K.; Li, B., et al. SIRT5 regulates the mitochondrial lysine succinyloyme and metabolic networks. Cell Metab 2013, 18, 920-933, doi:10.1016/j.cmet.2013.11.013.
97. Wu, J.Y.; Huang, T.W.; Hsieh, Y.T.; Wang, Y.F.; Yen, C.C.; Lee, G.L.; Yeh, C.C.; Peng, Y.J.; Kuo, Y.Y.; Wen, H.T., et al. Cancer-Derived Succinate Promotes Macrophage Polarization and Cancer Metastasis via Succinate Receptor. Mol Cell 2020, 77, 213-227.e215, doi:10.1016/j.molcel.2019.10.023.
98. Akram, M. Citric acid cycle and role of its intermediates in metabolism. Cell Biochem Biophys 2014, 68, 475-478, doi:10.1007/s12013-013-9750-1.
99. Connors, J.; Dave, N.; Van Limbergen, J. The Role of Succinate in the Regulation of Intestinal Inflammation. Nutrients 2018, 11, doi:10.3390/nu11010025.
100. Ariza, A.C.; Deen, P.M.; Robben, J.H. The succinate receptor as a novel therapeutic target for oxidative and metabolic stress-related conditions. Front Endocrinol (Lausanne) 2012, 3, 22, doi:10.3389/fendo.2012.00022.
101. de Castro Fonseca, M.; Aguilar, C.J.; da Rocha Franco, J.A.; Gingold, R.N.; Leite, M.F. GPR91: expanding the frontiers of Krebs cycle intermediates. Cell Commun Signal 2016, 14, 3, doi:10.1186/s12964-016-0126-1.
102. Toma, I.; Kang, J.J.; Sipos, A.; Vargas, S.; Bansal, E.; Hanner, F.; Meer, E.; Peti-Peterdi, J. Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J Clin Invest 2008, 118, 2526-2534, doi:10.1172/JCI33293.
103. Keiran, N.; Ceperuelo-Mallafré, V.; Calvo, E.; Hernández-Alvarez, M.I.; Ejarque, M.; Núñez-Roa, C.; Horrillo, D.; Maymó-Masip, E.; Rodriguez, M.M.; Fradera, R., et al. SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity. Nat Immunol 2019, 20, 581-592, doi:10.1038/s41590-019-0372-7.
104. Chouchani, E.T.; Pell, V.R.; Gaude, E.; Aksentijević, D.; Sundier, S.Y.; Robb, E.L.; Logan, A.; Nátodchoyi, S.M.; Ord, E.N.J.; Smith, A.C., et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature 2014, 515, 431-435, doi:10.1038/nature13909.
105. Rubio, T.; Lametschwandtner, G.; Jost, S.; Hinteregger, S.; Kund, J.; Carballido-Perrig, N.; Schwärzler, C.; Junct, T.; Voshol, H.; Meingassner, J.G., et al. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nat Immunol 2008, 9, 1261-1269, doi:10.1038/ni.1657.
106. Mills, E.L.; Kelly, B.; Logan, A.; Costa, A.S.H.; Varma, M.; Bryant, C.E.; Tourlomousis, P.; Däbritz, J.H.M.; Gottlieb, E.; Latorre, I., et al. Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages. Cell 2016, 167, 457-470.e413, doi:10.1016/j.cell.2016.08.064.
107. Haas, R.; Cucchi, D.; Smith, J.; Pucino, V.; Madougall, C.E.; Mauro, C. Intermediates of Metabolism: From Bystanders to Signalling Molecules. Trends Biochem Sci 2016, 41, 460-471, doi:10.1016/j.tibs.2016.02.003.
108. Warburg, O. Ueber den Stoffwechsel der Tumoren: Arbeiten aus dem Kaiser Wilhelm-Institut für Biologie, Berlin-Dahlem. JAMA: The Journal of the American Medical Association 1926, 1926, doi:10.1001/jama.1926.02680200071042.
109. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
110. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
111. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
112. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
113. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
114. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
115. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
116. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
117. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
118. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
119. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
120. Warburg, O.; Wind, E.; Negelein, E. The Metabolism of Tumors in the Body. JAMA: The Journal of the American Medical Association 1926, 87, doi:10.1001/jama.1926.02680200071042.
122. Papandreu, I.; Cairns, R.A.; Fontana, L.; Lim, A.L.; Denko, N.C. HIV-1 mediates adaptation to hypoxia by actively down-regulating mitochondrial oxygen consumption. Cell Metab 2006, 3, 187-197, doi:10.1016/j.cmet.2006.01.012.

123. Selak, M.A.; Armour, S.M.; MacKenzie, E.D.; Boulaibeh, H.; Watson, D.G.; Mansfield, K.D.; Pan, Y.; Simon, M.C.; Thompson, C.B.; Gottlieb, E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7, 77-85, doi:10.1016/j.cccr.2004.11.002.

124. Guzy, R.D.; Sharma, B.; Bell, E.; Chandel, N.S.; Schumacker, P.T. Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 2008, 28, 718-731, doi:10.1128/MCB.01338-07.

125. Koivunen, P.; Hirsilä, M.; Remes, A.M.; Hassinen, I.E.; Kivirikko, K.I.; Myllyharju, J. Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. Biol Cell 2007, 282, 4524-4532, doi:10.1016/j.bjpc.200614015200.

126. Bennousse, K.; Garade, J.; Acín-Pérez, R. How Mitochondrial Metabolism Contributes to Macrophage Phenotype and Functions. J Mol Biol 2018, 430, 3906-3921, doi:10.1016/j.jmb.2018.07.003.

127. Rodríguez-Prados, J.C.; Través, P.G.; Cuenca, J.; Rico, D.; Aragonés, J.; Martín-Sanz, P.; Cascante, M.; Boscá, L. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol 2010, 185, 605-614, doi:10.4049/jimmunol.0901698.

128. Palucka, K.; Banchereau, J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12, 265-277, doi:10.1038/nrc3528.

129. Cortese, M.; Sinclair, C.; Pulendran, B. Translating glycolytic metabolism to innate immunity in dendritic cells. Cell Metab 2014, 19, 737-739, doi:10.1016/j.cmet.2014.04.012.

130. Wooben, R.; Hüsecken, Y.; Lodewick, C.; Gibbert, K.; Fandrey, J.; Winning, S. Role of hypoxia inducible factor-1α for inter-feron synthesis in mouse dendritic cells. Biol Chem 2013, 394, 495-503, doi:10.1515/hsz-2012-0320.

131. Dang, E.V.; Barbi, J.; Yang, H.Y.; Jinasesa, D.; Yu, H.; Zheng, Y.; Bordman, Z.; Fu, J.; Kim, Y.; Yen, H.R., et al. Control of T(H)1/T(reg) balance by hypoxia-inducible factor 1. Cell 2011, 141, 772-794, doi:10.1016/j.cell.2011.07.033.

132. Weinberg, S.E.; Singer, B.D.; Steinert, E.M.; Martinez, C.A.; Mehta, M.M.; Martinez-Reyes, I.; Gao, P.; Helmin, K.A.; Abdala-Valencia, H.; Sena, L.A., et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature 2019, 565, 495-499, doi:10.1038/s41586-018-0846-z.

133. Li, Y.H.; Woo, S.H.; Choi, D.H.; Cho, E.H. Succinate induces hepatic fibrogenesis by promoting activation, proliferation, and migration, and inhibiting apoptosis of hepatic stellate cells. Biochem Biophys Res Commun 2015, 463, 853-858, doi:10.1016/j.bbrc.2015.06.023.

134. Park, S.Y.; Le, C.T.; Sung, K.Y.; Choi, D.H.; Cho, E.H. Succinate causes α-SMA production through GPR91 activation in hepatic stellate cells. Biochem Biophys Res Commun 2018, 496, 673-678, doi:10.1016/j.bbrc.2018.01.106.

135. Baek, J.H.; Zeng, R.; Weimann-Menke, J.; Valerius, M.T.; Wada, Y.; Ajay, A.K.; Colonna, M.; Kelley, V.R. IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease. J Clin Invest 2015, 125, 3198-3214, doi:10.1172/JCI81166.

136. Baek, J.H. The Impact of Versatile Macrophage Functions on Acute Kidney Injury and Its Outcomes. Front Physiol 2019, 10, 1016, doi:10.3389/fphys.2019.01016.

137. Baardman, J.; Verberk, S.G.S.; Prange, K.H.M.; van Weeghel, M.; van der Velden, S.; Ryan, D.G.; Wüst, R.C.I.; Neele, A.E.; Speijer, D.; Denis, S.W., et al. A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia. Cell Rep 2018, 25, 2044-2052.e2045, doi:10.1016/j.celrep.2018.10.092.

138. Parkandi, I.; Cairns, R.A.; Fontana, L.; Lim, A.L.; Denko, N.C. HIF-1 mediates adaptation to hypoxia by actively down-regulating mitochondrial oxygen consumption. Cell Metab 2004, 114, 1098-1106, doi:10.1172/JCI21086.

139. Macias-Ceja, D.C.; Ortiz-Masiá, D.; Salvador, P.; Gisbert-Ferrándiz, L.; Hernández, C.; Hausmann, M.; Rogler, G.; Esplugues, J.V.; Hinojosa, J.; Alós, R., et al. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res 2019, 565, 495-499, doi:10.1038/s41586-018-0807-3.

140. Ooi, M.; Nishiumi, S.; Yoshie, T.; Shiomi, Y.; Kohashi, M.; Fukunaga, K.; Nakamura, S.; Matsumoto, H.; Hatano, N.; Shino-hara, M., et al. GC/MS-based profiling of amino acids and TCA cycle-related molecules in ulcerative colitis. Inflamm Res 2011, 60, 831-840, doi:10.1007/s00011-011-0340-7.

141. Vernia, P.; Caprilli, R.; Latella, G.; Barbetti, F.; Magliocca, F.M.; Ciddor, M. Fecal lactate and ulcerative colitis. Gastroenterology 1988, 95, 1564-1568, doi:10.1016/S0016-5085(88)80078-7.

142. Hallert, C.; Björck, I.; Nyman, M.; Pousette, A.; Grännö, C.; Svensson, H. Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm Bowel Dis 2003, 9, 116-121, doi:10.1097/00054725-200303000-00005.

143. Osaka, T.; Moriyama, E.; Arai, S.; Date, Y.; Yagi, J.; Kikuchi, J.; Tsuneda, S. Meta-Analysis of Fecal Microbiota and Metabolites in Experimental Colitic Mice during the Inflammatory and Healing Phases. Nutrients 2017, 9, doi:10.3390/nu9121329.

144. Ariake, K.; Ohkusa, T.; Sakurazawa, T.; Kumagai, S.; Eishi, Y.; Hoshi, S.; Yajima, T. Roles of mucosal bacteria and succinic acid in colitis caused by dextran sulfate sodium in mice. J Med Dent Sci 2000, 47, 233-241.
147. Patrini, G.; Mandimika, T.; Butts, C.A.; Zhu, S.; Roy, N.C.; McNabb, W.C.; Ansell, J. Influence of dietary blueberry and broccoli on cecal microbiota activity and colon morphology in mdrla(-/-) mice, a model of inflammatory bowel diseases. Nutrition 2012, 28, 324-330, doi:10.1016/j.nut.2011.07.018.

148. Kajiwara, T.; Takeda, T.; Sakata, S.; Sakamoto, M.; Hashimoto, M.; Suzuki, H.; Suzuki, M.; Benno, Y. Change of intestinal microbiota with elemental diet and its impact on therapeutic effects in a murine model of chronic colitis. Dig Dis Sci 2009, 54, 1892-1900, doi:10.1007/s10620-008-0574-6.

149. Bar-Or, D.; Carrick, M.M.; Mains, C.W.; Rael, L.T.; Slone, D.; Brody, E.N. Sepsis, oxidative stress, and hypoxia: Are there clues to better treatment? Res Rep 2015, 20, 193-197, doi:10.1179/135100215Y.0000000005.

150. Aguilar, C.J.; Rocha-Franco, J.A.; Sousa, P.A.; Santos, A.K.; Ladeira, M.; Rocha-Resende, C.; Ladeira, L.O.; Resende, R.R.; Botoni, F.A.; Barrouin Melo, M., et al. Succinate causes pathological cardiomyocyte hypertrophy through GPR91 activation. Cell Commun Signal 2014, 12, 78, doi:10.1186/s12964-014-0078-2.

151. Sadagopan, N.; Li, W.; Roberds, S.L.; Major, T.; Preston, G.M.; Yu, Y.; Tones, M.A. Circulating succinate is elevated in rodent models of hypertension and metabolic disease. Am J Hypertens 2007, 20, 1209-1215, doi:10.1016/j.amjhypt.2007.05.010.

152. van Diepen, J.A.; Robben, J.H.; Hoovield, G.J.; Carmone, C.; Alsady, M.; Boutens, L.; Bekkenkamp-Grovenstein, M.; Hijmans, A.; Engelke, U.F.H.; Wevers, R.A., et al. Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. ISME J 2018, 12, 1642-1657, doi:10.1038/s41396-018-0068-2.

153. Cavalli, G.; Dinarello, C.A. Suppression of inflammation and acquired immunity by IL-37. Immunol Rev 2017, 281, 179-190, doi:10.1111/imr.12605.

154. Ryan, D.G.; O'Neill, L.A. Krebs cycle rewired for macrophage and dendritic cell effector functions. FEBS Lett 2017, 591, 2992-3006, doi:10.1002/1742-4682.12474.

155. Mills, E.L.; O'Neill, L.A. Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal. Eur J Immunol 2015, 46, 3-12, doi:10.1002/eji.201445427.

156. Ryan, D.G.; O'Neill, L.A.J. Krebs cycle cycle rewired for macrophage and dendritic cell effector functions. FEBS Lett 2017, 591, 2992-3006, doi:10.1002/1742-4682.12474.

157. Ashrafian, H.; Czibik, G.; Bellahcene, M.; Aksentijevich, D.; Smith, A.C.; Mitchell, S.J.; Dodd, M.S.; Kirwan, J.; Byrne, J.J.; Ludwig, C., et al. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab 2012, 15, 361-371, doi:10.1016/j.cmet.2012.01.017.

158. King, A.; Selak, M.A.; Gottlieb, E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006, 25, 4675-4682, doi:10.1038/sj.onc.1209594.

159. Humphries, F.; Shmuel-Galia, L.; Ketelut-Carneiro, N.; Li, S.; Wang, B.; Nemmara, V.V.; Wilson, R.; Jiang, Z.; Khalighinejad, F.; Munneuuddin, K., et al. Succination inactivates gasdermin D and blocks pyroptosis. Science 2020, 369, 1633-1637, doi:10.1126/science.abb9818.

160. Patil, N.K.; Bohannon, J.K.; Hernandez, A.; Patil, T.K.; Sherwood, E.R. Regulation of leukocyte function by citric acid cycle intermediates. J Leukoc Biol 2019, 106, 105-117, doi:10.1002/jlb.12170464.

161. Kelly, B.; O'Neill, L.A. Mitochondrial fumarate: Regulator of the immune system in the treatment of multiple sclerosis. J Cell Physiol 2019, 234, 9493-9555, doi:10.1002/jcp.29790.

162. Diebold, M.; Sievers, C.; Bantug, G.; Sanderson, N.; Kappos, L.; Kuhle, J.; Lindberg, R.L.P.; Derfuss, T. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. J Autoimmun 2018, 86, 39-50, doi:10.1016/j.jaut.2017.09.009.

163. Ghoreschi, K.; Brück, J.; Kellerer, C.; Deng, C.; Peng, H.; Rothfuss, O.; Hussain, R.Z.; Gocke, A.R.; Respa, A.; Glocova, I., et al. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J Exp Med 2011, 208, 2291-2303, doi:10.1084/jem.20100977.

164. Peng, H.; Gueruau-de-Arellano, M.; Mehta, V.B.; Yang, Y.; Huss, D.J.; Papenfuss, T.L.; Lovett-Racke, A.E.; Racke, M.K. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem 2012, 287, 28017-28026, doi:10.1074/jbc.M112.371397.

165. Linker, R.A.; Lee, D.H.; Ryan, S.; van Dam, A.M.; Conrad, R.; Bista, P.; Zeng, W.; Hronowsky, X.; Buku, A.; Chollate, S., et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134, 678-692, doi:10.1038/brainaww386.

166. Blewett, M.M.; Xie, J.; Zaro, B.W.; Backus, K.M.; Altman, A.; Teijaro, J.R.; Cravatt, B.F. Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells. Sci Signal 2016, 9, rs10, doi:10.1126/scisignal.aaf7694.
191. Arts, R.J.W.; Carvalho, A.; La Rocca, C.; Palma, C.; Rodrigues, F.; Belinha, A., et al. Immunometabolic Pathways in BCG-Induced Trained Immunity. Cell Rep 2016, 17, 2562-2571, doi:10.1016/j.celrep.2016.11.011.

192. Lu, C.; Ward, P.S.; Kapoor, G.S.; Rohle, D.; Turcan, S.; Abdel-Wahab, O.; Edwards, C.R.; Khanin, R.; Figueroa, M.E.; Melnick, A., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483, 474-478, doi:10.1038/nature10860.

193. Zuurbier, C.J.; Bertrand, L.; Beauloye, C.R.; Andreadou, I.; Ruiz-Meana, M.; Jespersen, N.R.; Kula-Alwar, D.; Prag, H.A.; Eric Botker, H.; Dambrova, M., et al. Cardiac metabolism as a driver and therapeutic target of myocardial infarction. J Cell Mol Med 2020, 24, 5937-5954, doi:10.1111/jcmm.15180.

194. Yang, M.; Pollard, S.P. Succinate Is Not Metabolized into Itaconate Intracellularly. J Biol Chem 2017, 292, 4766-4769, doi:10.1074/jbc.C117.775270.

195. El-Azzouny, M.; Tom, C.T.; Evans, C.R.; Olson, L.L.; Tanga, M.J.; Gallagher, K.A.; Martin, B.R.; Burant, C.F. Dimethyl Itaconate Is Not Metabolized into Itaconate Intracellularly. J Biol Chem 2017, 292, 4766-4769, doi:10.1074/jbc.C117.775270.

196. Ooi, A.; Wong, J.C.; Petillo, D.; Roossien, D.; Perrier-Trudova, V.; Whitten, D.; Min, B.W.; Tan, M.H.; Zhang, Z.; Yang, X.J., et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011, 20, 511-523, doi:10.1016/j.ccr.2011.08.024.

197. Brennan, M.S.; Matos, M.F.; Li, B.; Hronowski, X.; Gao, B.; Juhasz, P.; Rhodes, K.I.; Scannevin, R.H. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. PLoS One 2015, 10, e0120254, doi:10.1371/journal.pone.0120254.

198. Reisin, L.; Schneeweiss, A. Spontaneous disappearance of cough induced by angiotensin-converting enzyme inhibitors (captopril or enalapril). Am J Cardiol 1992, 70, 398-399, doi:10.1016/0002-9149(92)90630-H.

199. Sidibe, Y.; Ishii, Y.; Itoh, K.; Igarashi, K.; Katoh, Y.; Hayasy, N.; Satoh, K.; Hatayama, I., et al. An Nrf2/small MaF heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997, 236, 313-322, doi:10.1006/bbrc.1997.6943.

200. Kornberg, M.D.; Bhargava, P.; Kim, P.M.; Putluri, V.; Snowman, A.M.; Putluri, N.; Calabresi, P.A.; Snyder, S.H. Dimethyl succinate and Nrf2 signaling. Cancer Cell 2011, 20, 524-537, doi:10.1016/j.ccr.2011.09.006.

201. Kobayashi, E.; Suzuki, T.; Yamamoto, M. Roles nrf2 plays in myeloid cells and related disorders. Oxid Med Cell Longev 2013, 2013, 529219, doi:10.1155/2013/529219.

202. Ooi, A.; Wong, J.C.; Petillo, D.; Roossien, D.; Perrier-Trudova, V.; Whitten, D.; Min, B.W.; Tan, M.H.; Zhang, Z.; Yang, X.J., et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011, 20, 511-523, doi:10.1016/j.ccr.2011.08.024.

203. Adam, J.; Hatipoglu, E.; O’Flaherty, L.; Ternette, N.; Sahyal, N.; Lockstone, H.; Baban, D.; Nye, E.; Stamp, G.W.; Wolhuter, M., et al. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol Cell Biol 2004, 24, 36-45, doi:10.1128/mcb.24.1.36-45.2004.

204. Melnick, A., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483, 474-478, doi:10.1038/nature10860.

205. Kobayashi, E.H.; Suzuki, T.; Kawanishi, T.; Miraglia, A.; Ishii, T.; Igarashi, K.; Katoh, Y.; Oyake, T.; Hayasy, N.; Satoh, K.; Hatayama, I., et al. An Nrf2/small MaF heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997, 236, 313-322, doi:10.1006/bbrc.1997.6943.

206. Reisin, L.; Schneeweiss, A. Spontaneous disappearance of cough induced by angiotensin-converting enzyme inhibitors (captopril or enalapril). Am J Cardiol 1992, 70, 398-399, doi:10.1016/0002-9149(92)90630-H.

207. Thimmulappa, R.K.; Lee, H.; Kangasamy, T.; Reddy, S.P.; Yamamoto, M.; Kessler, T.W.; Biswal, S. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006, 116, 984-995, doi:10.1172/JCI25790.

208. Yoh, K.; Itoh, K.; Enomoto, A.; Hirayama, A.; Yamaguchi, N.; Kobayashi, M.; Morito, N.; Koyama, A.; Yamamoto, M.; Takahashi, S. Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 2001, 60, 1343-1353, doi:10.1046/j.1523-1755.2001.00939.x.

209. Van der Heijden, C.D.C.C.; Noz, M.P.; Joosten, L.A.B.; Netea, M.G.; Kornberg, M.D.; Bhargava, P.; Kim, P.M.; Putluri, V.; Snowman, A.M.; Calabresi, P.A.; Snyder, S.H. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science 2018, 360, 449-453, doi:10.1126/science.aan4665.

210. Kobayashi, E.; Suzuki, T.; Yamamoto, M. Roles nrf2 plays in myeloid cells and related disorders. Oxid Med Cell Longev 2013, 2013, 529219, doi:10.1155/2013/529219.

211. Brennan, M.S.; Matos, M.F.; Li, B.; Hronowski, X.; Gao, B.; Juhasz, P.; Rhodes, K.I.; Scannevin, R.H. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro. PLoS One 2015, 10, e0120254, doi:10.1371/journal.pone.0120254.
194. Ryan, D.G.; Murphy, M.P.; Frezza, C.; Prag, H.A.; Chouchani, E.T.; O’Neill, L.A.; Mills, E.L. Coupling Krebs cycle metabolites to signalling in immunity and cancer. Nat Metab 2019, 1, 16-33, doi:10.1038/s42255-018-0014-7.

195. Hirschey, M.D.; Zhao, Y. Metabolic Regulation by Lysine Malonylation, Succinylation, and Glutarylation. Mol Cell Proteomics 2015, 14, 2308-2315, doi:10.1074/mcp.R114.046664.

196. Bénit, P.; Letouzé, E.; Rak, M.; Aubry, L.; Burnichon, N.; Favier, J.; Gimenez-Roqueplo, A.P.; Rustin, P. Unsuspected task for an old team: succinate, fumarate and other Krebs cycle acids in metabolic remodeling. Biochim Biophys Acta 2014, 1837, 1330-1337, doi:10.1016/j.bbabio.2014.03.013.

197. Kaelin, W.G.; McKnight, S.L. Influence of metabolism on epigenetics and disease. Cell 2013, 153, 56-69, doi:10.1016/j.cell.2013.03.004.